Skip to main content
EXACT Therapeutics AS logo

EXACT Therapeutics AS — Investor Relations & Filings

Ticker · EXTX ISIN · NO0010852213 LEI · 2138006ZE5JAL39AGD55 OL Manufacturing
Open in API
Filings indexed 233 across all filing types
Latest filing 2023-09-28 Report Publication Anno…
Country NO Norway
Listing OL EXTX

About EXACT Therapeutics AS

https://www.exact-tx.com/

EXACT Therapeutics AS is a clinical-stage biopharmaceutical company developing its proprietary technology platform, Acoustic Cluster Therapy (ACT®), for targeted therapeutic enhancement. The ACT® platform uses ultrasound to amplify the effect of co-administered drugs, with a primary focus on oncology. Its biomechanical mode of action increases the local uptake of therapeutics from blood vessels into the surrounding tissue, including across the blood-brain barrier, without requiring drug reformulation. This non-invasive technology is designed to be compatible with standard ultrasound systems. The company's pipeline includes the ENACT study, a Phase 2 trial evaluating ACT® in patients with locally advanced pancreatic cancer, following the completion of the ACTIVATE Phase 1 study in patients with liver metastases.

Recent filings

Filing Released Lang Actions
EXACT Therapeutics announces first half 2023 interim results
Report Publication Announcement Classification · 99% confidence The document explicitly announces the 'first half 2023 interim results' for EXACT Therapeutics. This points directly to a comprehensive financial report covering a period shorter than a year, which corresponds to the Interim / Quarterly Report (IR) definition. Although it mentions that the 'interim report and presentation' are available elsewhere, the primary purpose of this text is the announcement of the results themselves, making 'IR' a stronger fit than 'RPA' (which is usually for the announcement of the publication timing). The length (2862 chars) is substantial enough to be the core announcement, not just a brief notice. Since it is an 'interim' report announcement, the code IR is selected.
2023-09-28 English
EXACT Therapeutics announces appointment of Caspar Foghsgaard as SVP Commercial & Business Development
Board/Management Information Classification · 100% confidence The document explicitly announces the appointment of a new Senior Vice President, Caspar Foghsgaard, to the leadership team, detailing his new role and previous experience. This directly corresponds to the definition of Board/Management Information (MANG), which covers announcements of changes in senior management.
2023-09-27 English
EXACT Therapeutics announces positive clinical results from the ACTIVATE Phase I dose escalation
Regulatory Filings Classification · 95% confidence The document is a press release from EXACT THERAPEUTICS AS announcing positive safety and anticancer activity results from the dose escalation part of their ACTIVATE Phase I trial. It details clinical findings, quotes the CMO, and provides background on the company and the ACT® technology. This type of announcement, focusing on clinical trial results and business updates outside of mandatory periodic financial filings (like 10-K or IR), is typically classified as an Earnings Release (ER) if it were quarterly results, or more generally, a Regulatory Filing (RNS) if it's a specific operational update not covered by other codes. Since it is a specific announcement of clinical results, it is not a full financial report (10-K, IR), a presentation (IP), or a management discussion (MDA). Given the context of a clinical result announcement, which often precedes a formal presentation or earnings call, and since it doesn't fit perfectly into the other specific categories, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback, although ER might be considered if it were tied to a reporting period. However, as a standalone announcement of clinical data, RNS is safer, or potentially LTR if the focus was on regulatory interaction, but here it's a positive result announcement. Given the options, RNS covers general corporate and operational announcements not explicitly defined elsewhere. The document length (3744 chars) is short, suggesting it's an announcement rather than a full report.
2023-09-26 English
EXACT Therapeutics announces positive clinical results from the ACTIVATE Phase I dose escalation
Earnings Release Classification · 90% confidence The document is a press release from EXACT Therapeutics announcing positive safety and anticancer activity results from the dose escalation part of their ACTIVATE Phase I clinical trial. It details preliminary findings, mentions future presentation plans, and provides company background. This type of announcement, focusing on key clinical trial outcomes released outside of a formal quarterly/annual filing, is best classified as an Earnings Release (ER) if it were financial results, but since it is purely clinical/scientific results announcement, it fits best under the general category for significant corporate news that isn't a specific regulatory form or a full report. However, given the options, this is a high-level announcement of results. Since it is not a full financial report (10-K, IR) or a transcript (CT), and it is not explicitly a management discussion (MDA) or an investor presentation (IP), it functions as a primary announcement of new data. In many databases, significant clinical updates released via press release are often grouped with Earnings Releases (ER) as they drive investor interest, or sometimes as Regulatory Filings (RNS) if no better fit exists. Given the content is a direct announcement of trial results, it is most analogous to an Earnings Release (ER) which announces period results, even though these are clinical results, not financial ones. If the data were presented in a formal presentation, it would be IP. Since it is a press release announcing results, ER is the closest fit for a primary results announcement, although RNS is a possibility if ER is strictly reserved for financial earnings. Given the context of driving investor awareness with key data, ER is chosen over the generic RNS. Q3 2023
2023-09-26 English
Invitation to first half results 2023 presentation of EXACT Therapeutics AS
Report Publication Announcement Classification · 98% confidence The document is an invitation announcing the release date and presentation details for the 'interim first half 2023 results' of EXACT Therapeutics AS. It explicitly states that the 'report for the first half year 2023 will be available' on a specific date and time, and invites participants to a presentation/Q&A session. Since the document itself is not the comprehensive financial report (IR) but rather the announcement *about* the report's release and associated presentation, it fits the definition of a Report Publication Announcement (RPA). The document length (1809 chars) is short, supporting the RPA classification over the full Interim Report (IR).
2023-09-19 English
Financial calendar
Report Publication Announcement Classification · 99% confidence The document text is extremely short (271 characters) and explicitly titled 'Financial calendar'. It lists future dates for company events, specifically mentioning the 'Half-yearly Report' release date (28.09.2023). This is not the report itself, but an announcement about the schedule of future reports. Since there is no specific category for a 'Financial Calendar', and it is an announcement regarding the publication of future reports, the most appropriate classification is Report Publication Announcement (RPA), as it announces when reports will be published. If it were announcing the immediate release of a report, RPA would still be the best fit over RNS, given the context of scheduling.
2023-09-13 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.